<DOC>
	<DOCNO>NCT01951027</DOCNO>
	<brief_summary>pharmacokinetics/pharmacodynamics GX-G3 single subcutaneous administration healthy male subject .</brief_summary>
	<brief_title>Phase I Study GX-G3 Healthy Subjects</brief_title>
	<detailed_description>MTD determine DLT occurrence frequency , severity charactoristic adverse event , vital sign , physical examination , ECG , Laboratory test , chest-X-ray examine safety evaluation . The second purpose evaluate pharmacokinetics pharmacodynamics , immunogenecity evaluate investigate antibody production .</detailed_description>
	<criteria>Subjects may enter study meet follow criterion : 1 . Are capable understand complying requirement study voluntarily sign informed consent form ( ICF ) ; 2 . Healthy male volunteer age 2045 year ; 3 . Have body weight 6090 kg ( inclusive ) , body mass index ( BMI ) equal great 19 less 27 kg/m2 ; 4 . Are eligible study base screen data ( Subjects may participate Investigator consider eligible look screen data ) ; Subjects present follow enter study : 1 . Have history current evidence disease ; 2 . Have percent white blood cell ( WBC ) neutrophil &gt; UNL ; 3 . Have count platelet &lt; 100,000/mm3 ; 4 . Have long length spleen &gt; 16 cm measure abdomen ultrasonography ; 5 . Have MSSBP ≥ 140 mmHg ≤ 90 mmHg and/or MSDBP ≥ 95 mmHg ≤ 50 mmHg ; ( BP must measure rest least 3 minute ) 6 . Have clinically significant arrhythmia EKG/ECG ; 7 . Are positive HBV , HCV , HIV ; 8 . Have history allergy/hypersensitivity ongoing allergy/hypersensitivity drug , judge investigator ; 9 . Have blood donation/ blood loss great 400 ml within 8 week prior dose ; 10 . Have participate another clinical trial investigational drug within 8 week screening period ; 11 . Any condition consider inappropriate unsafe subject Investigator ; 12 . Are consider ineligible investigator due physical finding laboratory value screen assessment ; 13 . Have history GCSF treatment ;</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>DLT</keyword>
	<keyword>Immunogenecity</keyword>
</DOC>